

# BIOGEN IDEC INC.

ISIN: **US09062X1037** WKN: **09062X103**

## Overview

2024/05/03 22:30:01	
<b>Price</b>	217.51 USD
<b>Difference</b>	<span style="color: green;">▲</span> 1.87% (4.00)

General attributes	
ISIN	US09062X1037
Symbol	BIIB
Exchange	Nasdaq
Currency	USD
Sector	Chemical / Pharmaceutical / Health
Security type	Stock
Market cap (m)	29,515 EUR
Benchmark	S&P 500

Market data	
Bid (Bid size)	217.78 USD (100)
Ask (Ask size)	219.00 USD (100)
Open	215.30 USD
High	217.88 USD
Low	213.11 USD
Close (prev. day)	213.51 USD
VWAP	216.5249 USD
Volume (pcs)	1,144,154
Trading volume	247,570,362.58
Number of trades	28,160
Last size	-

Futures and Options	
Related Futures	-
Related Options	-

PDF Downloads	
Company report: BIOGEN IDEC INC.	<a href="#">Download</a>



Information about previous performance does not guarantee future performance.  
Source: FactSet

### Recent research

on sector		on market	
Date		Headline	Download
2024/04/26		Global Equity Ratings	<a href="#">Download</a>
2024/04/03		Global Equity Ratings	<a href="#">Download</a>
2024/03/13		Global Equity Ratings	<a href="#">Download</a>
2024/02/22		Global Equity Ratings	<a href="#">Download</a>
2024/02/14		Global Equity Ratings	<a href="#">Download</a>

## Details

2024/05/03 22:30:01

**Price**

217.51 USD

**Difference** ▲ 1.87% (4.00)

**General attributes**

**ISIN** US09062X1037

**Symbol** BIIB

**Exchange** Nasdaq

**Currency** USD

**Sector** Chemical / Pharmaceutical / Health

**Security type** Stock

**Market cap (m)** 29,515 EUR

**Benchmark** S&P 500

**Market data**

**Bid (Bid size)** 217.78 USD (100)

**Ask (Ask size)** 219.00 USD (100)

**Open** 215.30 USD

**High** 217.88 USD

**Low** 213.11 USD

**Close (prev. day)** 213.51 USD

**VWAP** 216.5249 USD

**Volume (pcs)** 1,144,154

**Trading volume** 247,570,362.58

**Number of trades** 28,160

**Last size** -

**Performance and Risk**

	6m	1Y	3Y
<b>Perf (%)</b>	-12.82%	-30.06%	-20.99%
<b>Perf (abs.)</b>	-31.99	-93.49	-57.80
<b>Beta</b>	0.83	0.70	0.80
<b>Volatility</b>	27.48	23.44	39.20

5Y



Information about previous performance does not guarantee future performance.  
Source: FactSet

**Price data**

<b>Ø price 5 days   Ø volume 5 days (pcs.)</b>	215.49 USD (1,246,397)
<b>Ø price 30 days   Ø volume 30 days (pcs.)</b>	205.96 USD (1,279,468)
<b>Ø price 100 days   Ø volume 100 days (pcs.)</b>	229.46 USD (1,219,511)
<b>Ø price 250 days   Ø volume 250 days (pcs.)</b>	252.32 USD (1,091,793)
<b>YTD High   date</b>	268.30 USD (2024/01/03)
<b>YTD Low   date</b>	189.44 USD (2024/04/19)
<b>52 Weeks High   date</b>	319.76 USD (2023/06/12)
<b>52 Weeks Low   date</b>	189.44 USD (2024/04/19)

**All listings for BIOGEN IDEC INC.**

Exchange	Date	Time	Price	Trading volume (mio.)	Number of trades
Xetra	2024/05/03	17:35	199.50 EUR	0.02	6
Vienna Stock Exchange	2024/05/03	17:32	199.25 EUR	0.00	2
Tradegate	2024/05/03	22:26	202.10 EUR	0.16	21
Stuttgart	2024/05/03	19:26	200.10 EUR	0.00	7
SIX Swiss Exchange	2022/	17:36	222.00 CHF	0.00	1

	09/28					
Nasdaq	2024/ 05/03	22:30	217.51 USD	247.57		28,160
Munich	2024/ 05/03	08:00	198.70 EUR	0.00		2
London Stock Exchange	2024/ 04/29	16:12	217.62 USD	0.00		1
Hanover	2024/ 05/03	08:02	198.65 EUR	0.00		3
Hamburg	2024/ 05/03	08:00	198.70 EUR	0.00		3
Frankfurt	2024/ 05/03	16:02	199.15 EUR	0.00		3
Euronext Milan MTF Trading After Hours	2024/ 04/15	18:43	188.00 EUR	0.00		2
Euronext Milan MTF Global Equity Market	2024/ 05/03	17:44	199.65 EUR	0.01		2
Duesseldorf	2024/ 05/03	19:31	199.60 EUR	0.00		5
Berlin	2024/ 05/03	20:21	200.80 EUR	0.00		17

## Company profile

### Company Logo



### Contact Details

BIOGEN INC.

--

225 Binney Street - 02142 Cambridge

Telefon: +1-617-679-2000

Fax: +

E-mail: [info@biogen.com](mailto:info@biogen.com)

### PDF Downloads

Company report: BIOGEN IDEC INC.



### Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

### Members of Management Board

Caroline Dorsa Chairman of Board of Directors

Eric Rowinsky Member of Board of Directors

Maria Freire Member of Board of Directors

Stephen Sherwin Member of Board of Directors

Jesus Mantas Member of Board of Directors

Monish Patolawala Member of Board of Directors

Susan Langer Member of Board of Directors

William Hawkins Member of Board of Directors

Chris Viehbacher Chairman of Managing Board

Ginger Gregory Member of Executive Committee

Michael McDonnell Member of Executive Committee

Nicole Murphy Member of Executive Committee

Priya Singhal Member of Executive Committee

Rachid Izzar Member of Executive Committee

Susan H. Alexander Member of Executive Committee